arrow
A

Ambarish Pandey

ut southwestern medical center
H指数:73
被引数:3.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trial

射血分数降低的心力衰竭的多药复方片:POLY-HF随机试验

2026-07-020
OAAI
Effects of semaglutide in obesity-related heart failure with preserved ejection fraction across the age spectrum: Findings from the STEP-HFpEF programme

司美格鲁肽在肥胖相关的心衰伴射血分数保留中不同年龄范围的效果:STEP-HFpEF项目的发现

2025-11-250
OAAI
Clinical Outcomes and Healthcare Costs in Patients Hospitalized With Heart Failure and Transthyretin Amyloid Cardiomyopathy: Findings From GWTG–HF

心力衰竭和甲状腺素转运蛋白淀粉样变性心肌病患者住院的临床结局与医疗成本:GWTG–HF研究的结果

2025-11-080
PRE
Predicting Heart Failure From 12-Lead ECGs Using AI: A HeartShare/AMP-HF Pooled Cohort Analysis

基于AI从12导联心电图预测心力衰竭:一项HeartShare/AMP-HF合并队列分析

JACC
IF0
2025-11-080
PRE
Rationale, Design, and Baseline Characteristics of the Polypill for Heart Failure with Reduced Ejection Fraction (POLY-HF) Trial

背景、设计与基线特征:心力衰竭伴射血分数降低的复方制剂试验(POLY-HF试验)

2025-10-310
PRE
Artificial Intelligence in Valvular Heart Disease

瓣膜性心脏病中的人工智能

2025-10-270
PRE
Effect of glucagon-like peptide-1 receptor agonists on heart failure outcomes and cardiovascular death across varying cardiovascular-kidney-metabolic comorbidity

胰高血糖素样肽-1受体激动剂对心力衰竭结局及心血管死亡的影响:横跨不同心血管-肾脏-代谢合并症的研究

2025-09-220
PRE
Frailty and Effects of Semaglutide in Obesity-Related HFpEF

虚弱及司美格鲁肽在肥胖相关HFpEF中的效果

2025-09-150
OAAI
Circulating ketone bodies and risk of incident atrial fibrillation: insights from the MESA and UK Biobank cohorts

循环酮体与心房颤动发生风险:MESA和UK Biobank队列研究的启示

2025-09-011
PRE
PRIME 2.0: An Update to The Proposed Requirements for Cardiovascular Imaging-Related Machine Learning Evaluation Checklist

PRIME 2.0:心血管成像相关机器学习评估清单的拟议要求更新

2025-08-270
PRE
Incretin-based therapies for individuals with obesity and heart failure with mildly reduced or preserved ejection fraction: A systematic review and meta-analysis of randomized controlled trials

基于肠促胰岛素的治疗方法用于肥胖合并轻度降低或保留射血分数的心力衰竭患者:一项随机对照试验的系统评价和荟萃分析

2025-06-110
PRE